You are here: Industry Insights > saRNA

News List

Eli Lilly and MiNA Therapeutics enter saRNA-based drug research deal pharmaceutical-technology
May 26, 2021
RNA therapy, which selectively activates a specific gene in a patient’s cells, has the potential to treat a wide range of diseases, including cancer.
Lilly and MiNA Therapeutics enter deal to develop saRNA-based drugs pharmaceutical-technology
May 13, 2021
Eli Lilly and MiNA Therapeutics have entered a global research partnership to develop new drug candidates using the latter’s small activating RNA (saRNA) technology platform.
Servier and MiNA Therapeutics ink neurology pact pharmatimes
January 25, 2021
French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
MiNA Therapeutics, AstraZeneca partner for metabolic diseases pharmaceutical-technology
January 13, 2020
UK-based MiNA Therapeutics has entered into a research collaboration agreement with AstraZeneca to assess small activating RNA (saRNA) molecules in metabolic diseases.
CEPI, Imperial College partner for emerging diseases vaccines pharmatimes
December 11, 2018
The Coalition for Epidemic Preparedness Innovations (CEPI) and Imperial College London have announced a partnership to develop a self-amplifying RNA vaccine platform (saRNA), enabling tailored vaccine production against multiple viral pathogens.